Phase I study of weekly maytansine given by iv bolus or 24-hour infusion.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001853:Bone Marrow / Q000187:drug effects; D002648:Child; D004064:Digestive System / Q000187:drug effects; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D008099:Liver / Q000187:drug effects; D008297:Male; D008453:Maytansine / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D009420:Nervous System / Q000187:drug effects; D010078:Oxazines / Q000627:therapeutic use*
D010078:Oxazines; D008453:Maytansine